Bg Medicine Inc · OTC:BGMD
Bg Medicine — Investor Presentation (February 2012)
35 slides from Bg Medicine's investor presentation, Feb 13, 2012
Slide 1: BG Medicine Investor Analyst Briefing, February 13, 2012
Exhibit 99.1 February 13, 2012 BGMEDICINE
Slide 2: Forward-Looking Statements
Forward-Looking This assumptions from We on Medicine’s All BGMEDICINE Form statements refer presentation these 10-Q, you expectations. projections and tocontained and the are contains Statements its documents based current orGiven inforward-looking forward-looking on thisthe reports that these prese
Slide 3: BG Medicine overview
BG Medicine 2000: 2005: 2006: 2007: Nov 2Dec BGMEDICINE 2011: 2010: founded began in-licensed CardioSCORE received transition HRP overview on rights the Initiative FDA concept totodeveloping 510k FDA galectin-3 andthat clearance submission development oneproprietary cannot for galectin-3 of predict
Slide 4: BG Medicine Content
BG Medicine Content Innovative, Focus Addressing Galectin-3 CardioSCORE Leveraging 3Robust, BGMEDICINE onproprietary diagnostic cardiovascular –hardware-independent, world-class today’s redefining business – potential company largest biomarker model heart partnerships market paradigm unmet developin
Slide 5: CardioSCORE vision: improved CVD risk prediction
CardioSCORE BGMEDICINE biological improved CVD signature vision: risk for prediction
Slide 6: Cardiovascular disease today
76out 1Today…… US Every an 33 of 33% #1 Heart Medicare American 52012 BGMEDICINE US American million expenditure adults Jan of disease adults minute 33;125(1):e2-e220. expenditure at Heart risk have are dies is the Association obese for of hypertension high #1 aDiabetes coronary US cholesterol Stati
Slide 7: Most cardiovascular events occur in low or medium risk individuals
of individuals >70% …But… Today…… in medium Framingham Murphy 6optimal BGMEDICINE cardiovascular use TP, riskof Dhangana based Risk who theevents Framingham-based Score are on low R,occur etoral. Performance risk assessment. of current Atherosclerosis. guidelines for coronary 2011 Jun;216(2):452-7.
Slide 8: Dr. Aram V. Chobanian
Aram Previously Honored American Chaired the of 7Dr. BGMEDICINE Vascular AHA. Chobanian V. several Chobanian, asHeart served Biology, thereceived has recipient scientific Association as been Heart MD President his on of Dr. committees Disease numerous the Bachelor (AHA), Chobanian of first Boston an
Slide 9: Deaths attributable to cardiovascular disease 1900-2008
0 1900 1910 200 400 600 800 1000 1200 Deaths 2008 2005 2000 1990 1980 1970 1960 1950 Heldenreich attributable in Thousands P1920 A et1930 al. to cardiovascular Circulation 1940 2011:123:933-944 disease (United States: 1900-2008).
Slide 10: Projected direct and indirect costs of CVD
02Projected 100 200 300 400 500 600 700 800 900 Billions 2030 2029 2028 2027 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Indirect Heidenreich 010 Direct 2008$ direct PA et and al.indirect Circulation costs2011;123:933-944 of all CVD, 2010 to 2030 (in billions 2008
Slide 11: Natural history of atherothrombosis
NATURAL INFARCT AGE 0C 10 20 30 40 50 60 70 COMPLICATED CALCIFICATION FIBROUS THROMBOSIS ULCERATION, HEMORRHAGE, FATTY From ed. LINICAL Fuster IN McGill STREAK YEARS V, STROKE PLAQUE HORIZON HISTORY Topol HC and LESION: EJ,GANGRENE McMahan and OF ATHEROTHROMBOSIS NabelCA, EG. ANEURYSM “Overview.” Ph
Slide 12: Cross-section of coronary artery with ruptured plaque
Cross-Section From Atherothrombotic Topol Choudhury EJ, and Nabel of Human etDisease.” al., EG.“Evolving Coronary Philadelphia: In Atherothrombosis Invasive Artery Lippincott with andRuptured Noninvasive and Williams Coronary Plaque &Imaging Wilkins, Artery and Thrombosis Techniques Disease, 2005. e
Slide 13: Major cardiovascular risk factors
Cardiovascular Hypertension Major C-reactive Other Age, male gender, protein Dyslipidemias Risk Kidney FHFactors premature dysfunction Tobacco CVDuseIL-6; Diabetes fibrinogen Obesity Arterial Physical calcium inactivity
Slide 14: Framingham Risk Score has low predictive value
Framingham Low Predictive In Atherosclerosis Overall, prospective = less 70% Value than Risk orCardiovascular 2012;216:452-7) 10% more inScore Clinical risk of individuals forTrials CVD Health inwho and 10 years develop ARICIntermediate studies, coronary lessdisease =than 10-20% one-fourth have risk
Slide 15: Coronary calcium score: advantages and disadvantages
Coronary Potential Calcium May Cost Disadvantages Radiation Insufficient improve ($200-400 deposits Advantages Calcium exposure data risk average) asin prediction Score yet (equivalent atherosclerotic ontovalue Predict when to for33 combined Cardiovascular plaques making chest X-rays) High clinical
Slide 16: BG Medicine vision: identify individuals at risk of a cardiovascular event
BG Medicine Out individuals 100 15 BGMEDICINE of experiencing VISION a cardiovascular event
Slide 17: Framingham risk score and traditional risk factors
BG Medicine Out experiencing individuals cardiovascular >70% medium Framingham FRS cholesterol, smoking, Murphy optimal BGMEDICINE of comprises of 100 use TP, risk them age, HDL-C, of Dhangana based Risk aVISION gender the are event traditional 16Framingham-based Score atonlow blood R,or et risk pre
Slide 18: CardioSCORE improves risk prediction with a blood test
BGdramatically To the traditional assessment, performed blood BGMEDICINE risk Medicine sample prediction risk onwith VISION afactor standard 17 improve a beyond test
Slide 19: CardioSCORE discovery and development
“Cardiology Motivating 1. are 2. additive will risk with associated 83 identified protein blood candidate 620 molecules 22 traditional 7paugment factors panel Clinical finalized algorithm BGMEDICINE 2011 2010-11 2009 2008 6600 947 751 subjects 50 CardioSCORE rotein Assessment Molecular present predi
Slide 20: BioImage Study design
Theyears Conducted Valentin Erling Enrolled N=7,687 Men •Baseline N=6,600 2.5 First N=292 myocardial Male 44.1% 55.9% Gender 3% 15% 74% Race AfricanAmerican White 55-65 28% 40% 32% Age 19 2% BioImage (55-80 cardiovascular Female 66-70 Falk, 6% Fuster, 1Q08 median blood as infarction, yrs) MD, 71-80
Slide 21: CardioSCORE event-free survival in BioImage
CardioSCORE Baseline Low 1Event-free CardioScore Score= •at 5P<0.0001 Months 20 28% 60% 26% 54% 0.99 10 1215 24 (N=2678) months Sensitivity 0.98 0.0-3.9 4.0-5.3 5.4-10.0 20 ofFramingham for Followup Survival 25 0.97 LOW difference 30 in Med 0.96 (FRS (CardioSCORE+FRS) the CardioScore Among (N=3017)
Slide 22: Primary event rates by Framingham category and CardioSCORE value
Primary Events 45 LOW CardioSCORE 42.58 29.68 12.24 25.12 17.11 9.82 21.91 13.92 11.58 MED HIGH Low (<10%) Framingham BGMEDICINE 40Intermediate (4.0-5.3) 35 (<4.0) (>5.3) per (10-20%) event 301000 25 risk rates in 20 21 patient-years category the High (>20%) 15byBioImage 10Framingham 50 Study risk c
Slide 23: BioImage Study: incidence of first cardiovascular event
BioImage primary 292 subjects 6600 BGMEDICINE endpoint Study:22Incidence events of First Cardiovascular Event
Slide 24: CardioSCORE doubles sensitivity with Framingham
CardioSCORE Today With 25% Doubling P BGMEDICINE < 0.0001 to CardioSCORE with 56% theFramingham sensitivity +23 Framingham + Framingham Risk Score, Risk Score Risk of 292 Score, vssubjects Framingham 56%who of these had Risksubjects a Score primary alone were event identified during the at baseline
Slide 25: CardioSCORE product overview
7 FDA Standard 510k based Use: term and older Score 30% CardioSCORE Aggregate immunoassays: Patent estimated BGMEDICINE death As risk increased submitted and from on protection: cleared an the blood for women 2030 for reimbursement aid 0.0 major following men in immunoassays risk Product increment t
Slide 26: Potential CardioSCORE market opportunity
Potential Total >800M TriMark BGMEDICINE Cholesterol tests Publications market per25 year opportunity Test“Cardiac marketfor world Marker CardioSCORE wide Diagnostic Testing Markets,” March 2011
Slide 27: Galectin-3: Redefining Heart Failure
Redefining Heart Failure Galectin-3: BGMEDICINE
Slide 28: Heart failure burden and need for early detection
What NORMAL Dilation: Thickened •Disorder 1Lifetime HF estimated $39B hospital >60% Lloyd-Jones Early Graphics BGMEDICINE As Slow, Chronic Identifying inhospital million 5a detection 15 is US consequence, for clinically Heart readmission risk in Systolic courtesy condition annual lung myocardium; HE
Slide 29: Galectin-3 mediated myocardial fibrosis and remodeling
Galectin-3 Remodeling Myocardial resulting leading Sharma to 2009, infibrosis activates scar etc. formation and fibroblast collagen andcells cardiac deposition … remodeling, … hallmarks of heart failure
Slide 30: Galectin-3 test utility and channels
NYHA MD Galectin-3 (>21,000 Studies Heart NONE Channels Individual Primary Framingham, PRE-HEART Finding PROVE-IT: Pre-HF PCP, Treatment Lifestyle Consumer/Professional: CORONA, US EU Gal-3 CLASS KNOWN Patient CAR, Decision: Professional: CARDIAC Heart Type CAR Failure mediated Heart profile is has
Slide 31: Galectin-3 awareness 2009-2011
Galectin-3 Awareness 56% 67% 83% 38% 29% 2009 Heart Primary Cardiologist Lab Source, BGMEDICINE Manager 53% 37% 25% 2010 Failure Sep Dec care 15% Awareness 2011 of2009 2010 2011 physician Specialists Galectin-3 30Data: Data: inLeerink Leerink the in the USUS: Swann, Swann, 2009-2011 Survey Survey of
Slide 32: Galectin-3 indications and expected milestones
Galectin-3 PIVOTAL FEASIBILITY INDICATION Aid HF-ACTION HF Framingham Heart (second PRIDE; Prognosis (extension Treatment Pre-eclampsia Renal BGMEDICINE (first inFailure Disease the indication) DECIDE-HF indication) in prognosis Response EXPECTED of Label Acute Heart first Risk Screening Risk RESEAR
Slide 33: Galectin-3 label extension market potential
Today’s TAKEAWAYS: New 20M LABEL TODAY 200M 75 125.5 High other 8.5 14 5.8 Infarction Post-myocardial 13.5 Diagnosed 1.1 1.7 Heart hospitalization 1Aid 32Circulation. BGMEDICINE AHA Bluemink Management –M Min 81 M indications Blood risk (EU)3 Failure: Failure failure M (US)1 (US) (EU) the Heart (EU)
Slide 34: Galectin-3 business model and roadmap
Galectin-3 Business Manual Automated 1st CPT Nov LabCorp Expected LDT ACC Abstract Presentation BGMEDICINE automated 2010 Code partners 2012 test title: Health Model: launch Feb Framingham roadmap conference Platforms kits time: “Galectin-3, partner 2011 33 Diagnostics Expected Saturday May now inEx
Slide 35: Goals for 2012
Goals BG Galectin-3’s CardioSCORE: Vast Galectin-3 CardioSCORE BGMEDICINE Medicine: Medicine commercial for 2012: IPlaunch protected evolves on 510k IP double 34 opportunity the protected oncleared move into automated the until asensitivity to until commercial by 2026, ahead transform FDA 2030, plat